Lifestyle
- Regular exercise
- Stress management techniques
- Adequate sleep
Immunoglobulin A · IgA · Salivary IgA
IgA measures the concentration of immunoglobulin A antibodies, which are crucial for mucosal immunity.
Reference ranges may vary slightly based on laboratory standards and population demographics.
Immunoglobulin A (IgA) is a critical antibody in the immune system, primarily found in mucosal areas such as the gut, respiratory tract, and urogenital tract, as well as in saliva, tears, and breast milk. It plays a vital role in mucosal immunity by preventing the colonization of pathogens and neutralizing toxins. Clinically, IgA is significant in diagnosing and understanding autoimmune conditions like IgA nephropathy (IgAN), where abnormal IgA deposits in the kidneys lead to inflammation and potential kidney damage. Elevated IgA levels can indicate autoimmune diseases, chronic infections, or liver disease, while low levels may suggest immunodeficiency. For athletes and biohackers, IgA levels can reflect immune function and stress response, with salivary IgA being a non-invasive marker of mucosal immunity and stress. However, IgA levels can be influenced by factors such as recent infections, stress, and certain medications. Time-of-day variations and fasting status are generally not significant confounders for IgA measurements, but individual variability and specific health conditions should be considered.
Klinische Bedeutung
Elevated IgA levels may indicate autoimmune diseases such as IgA nephropathy, chronic infections, or liver disease. Reduced IgA levels can suggest immunodeficiency or genetic conditions affecting antibody production.
Progressively rising IgA levels may indicate worsening autoimmune activity or chronic infection. Re-test in 4-6 weeks if elevated.
Falling IgA levels could suggest improvement in autoimmune conditions or resolution of infection.
Re-test Interval
4-6 weeks if outside optimal range
Note:
Consult a healthcare provider before starting new supplements, especially if you have underlying health conditions.
IgA levels can vary throughout the day; consistent timing is recommended for follow-up tests.
Testing Frequency
Annually for general health monitoring, more frequently if monitoring specific conditions.
Correlated with
Current research suggests that reference ranges and optimal targets for immunoglobulin A (IgA) in various autoimmune conditions, such as IgA nephropathy and CNS demyelination, remain poorly defined. Researchers have not yet established the role of IgA-containing immune complexes as reliable biomarkers for treatment response in IgAN. Additionally, clinical questions remain unanswered regarding the long-term implications of isolated MOG-IgA in CNS demyelinating diseases and its potential as a diagnostic tool.
901
Total Citations
11
Human/RCT
7.6
Avg. Influence
2025
Latest
This study examined the effects of L-Theanine on stress responses, revealing that it significantly reduced heart rate and salivary immunoglobulin A (s-IgA) during stress tasks. Researchers observed that these effects were likely due to decreased sympathetic nervous system activation.
This study examined Immunoglobulin A nephropathy (IgAN), the most common primary glomerulonephritis, which can lead to chronic kidney disease in up to 40% of patients. Researchers found significant variability in disease progression and outcomes among different racial and ethnic groups. Current diagnosis requires a kidney biopsy, as no specific biomarker is available.
Researchers identified that gut microbiota-specific IgA+ B cells can traffic to the central nervous system (CNS) in multiple sclerosis (MS). The study found a strong IgA enrichment in active MS, suggesting a role for IgA in neuroinflammation. This highlights the potential of IgA as a biomarker for MS.
Researchers found that Telitacicept treatment in patients with Immunoglobulin A nephropathy led to significant reductions in circulating galactose-deficient IgA1 and IgA-containing immune complexes. These changes were associated with decreased proteinuria, indicating potential biomarkers for treatment response.
This study investigated the presence of Immunoglobulin A antibodies against myelin oligodendrocyte glycoprotein (MOG) in patients with central nervous system demyelination. Researchers found isolated MOG-IgA in a small subgroup of patients, suggesting it may serve as a novel diagnostic biomarker.
Researchers explored the role of microscopic hematuria as a potential risk factor for progression in immunoglobulin A nephropathy (IgAN). The study discussed the challenges in standardizing hematuria assessments and called for its inclusion in clinical decision-making to guide treatment strategies in IgAN.
Researchers reported two cases of Immunoglobulin A vasculitis following COVID-19 vaccination, noting symptoms such as palpable purpura and arthritis. The study suggests a potential link between the vaccine and the onset of IgA vasculitis, although coincidence cannot be ruled out.
This study focused on the role of Immunoglobulin A in response to SARS-CoV-2 infection, emphasizing its significance as a mucosal antibody. Researchers noted that IgA could serve as a diagnostic and prognostic biomarker for COVID-19, highlighting its potential in early detection.
This study examined post-transplant Immunoglobulin A deposition in allografts, finding that latent mesangial IgA deposition can occur without urinary abnormalities. Researchers highlighted the need for further investigation into biomarkers that could predict progression to symptomatic IgA nephropathy.
Researchers found that Immunoglobulin A nephropathy (IgAN) involves complex immune injury mechanisms, suggesting a new 'spiral hypothesis' for its pathogenesis. The study highlights emerging targeted therapies that address both upstream and downstream disease processes. It emphasizes the importance of biomarker-guided personalized treatment strategies.
Research publications about Immunglobulin A over time
10totalLog lab results, track trends and optimize your biomarkers over time.
This page is for informational and research purposes only. All information is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. Many substances listed may not be approved for human use and may be subject to drug regulation laws (e.g., AMG in Germany, FDA in the US). PepStack does not encourage the use of any substance on humans. Always consult a qualified healthcare professional before making any health-related decisions. Use of this information is entirely at your own risk. PepStack assumes no liability for the accuracy, completeness, or timeliness of the content provided. Full disclaimer